Dr. Ramakrishna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
725 Welch Rd
Palo Alto, CA 94304Phone+1 650-497-8000Fax+1 650-497-8959
Summary
- Sneha Ramakrishna, M.D., is an Instructor of Pediatrics in the Division of Hematology and Oncology, working with Dr Crystal Mackall. Dr. Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. She completed her residency training in Pediatrics at the Children’s Hospital of Philadelphia and her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program. Her research focuses on identifying mechanisms of relapse in patients following chimeric antigen receptor (CAR) T cell therapies and optimizing both CAR design and tumor sensitivity to improve long-term success of CAR T cell therapies.
Education & Training
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2015 - 2018
Children's Hospital of PhiladelphiaResidency, Pediatrics, 2012 - 2015
Case Western Reserve University School of MedicineClass of 2012
Certifications & Licensure
CA State Medical License 2018 - 2026
MD State Medical License 2015 - 2019
PA State Medical License 2012 - 2015- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Start of enrollment: 2017 Oct 20
- CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Start of enrollment: 2020 Jan 10
- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) Start of enrollment: 2020 Jun 04
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsTumor inflammation-associated neurotoxicity.Jasia Mahdi, Jorg Dietrich, Karin Straathof, Claire Roddie, Brian J Scott
Nature Medicine. 2023-04-01 - 17 citationsImmune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault
Cancer Cell. 2024-01-08 - 394 citationsGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.Robbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy
Nature. 2022-03-01
Abstracts/Posters
- Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) TransductionSneha Ramakrishna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)Sneha Ramakrishna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Team Science Award Recognizes 8 Pediatric Cancer Researchers at StanfordApril 28th, 2021
Grant Support
- Research Scholars GrantHyundai Hope On Wheels2020–2022
External Links
- Stanford Biohttps://profiles.stanford.edu/sneha-ramakrishna
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
